Home / Market News / $HCA
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Bernstein Raises HCA Healthcare Price Target to $471

Nov 5, 2026, 3:02 AM UTC · Primary ticker $HCA

Bernstein analyst Lance Wilkes has increased the price target for HCA Healthcare from $426 to $471, while maintaining a 'hold' rating. This adjustment reflects a revised valuation assessment for the healthcare provider, suggesting a moderately positive sentiment from the analyst, though not an upgrade in recommendation.

Bernstein analyst Lance Wilkes raised HCA Healthcare's price target from $426 to $471. This indicates a more optimistic valuation perspective from the firm, suggesting potential upside for the stock according to their model. While the 'hold' rating remains, the increased price target could provide a modest positive sentiment boost for HCA shares in the short term, as it signals a higher perceived intrinsic value. For traders, this presents a potential opportunity if the market reacts positively to the revised target, though the unchanged 'hold' rating tempers strong bullish conviction. The long-term implications depend on whether HCA's operational performance can justify this higher valuation.

$HCA positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.